Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb”In the company’s words, NCT06544330 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma and 2 more
- Main trialPhase 1
- “This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.”In the company’s words, NCT06544330 on ClinicalTrials.gov
Other drugs for Systemic Lupus Erythematosus
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis Pharmaceuticals · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up2
- Apr 2028Phase 1 trial completes · ClinicalTrials.gov
- 24 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Apr 2028 | A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease | |
| Phase 1Active, not recruiting | 24 Jun 2028 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026